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Outcomes reported 
The LOTT Protocol specified 17 hypotheses, 14 of which are addressed in this manuscript.  The outcomes of 
maintenance of nutritional status and risk of cardiovascular disease will be addressed in secondary publications.  
Neurocognitive assessment was not included in the LOTT data collection schedule so that hypothesis cannot be 
addressed.  
 
Methods for assessing resting and exercise desaturation 
Resting and exercise desaturation were assessed with the Masimo Radical 7® pulse oximeter (Irvine, CA); the 
sampling rate was once every second and once every 2 seconds for the resting and exercise assessments, 
respectively.  Resting saturation was calculated as the mean of the acceptable quality samples obtained in the last 
5 minutes of a 6-minute test session; the coefficient of variation of the samples had to be ≤2.5%.  Exercise 
desaturation was assessed during the 6-minute walk; desaturation was rated severe if any mean of 30 consecutive 
samples (≥20 having acceptable quality) was <80%, and was rated moderate if 5 consecutive samples (all having 
acceptable quality) were <90% and severe exercise desaturation was not present.  
 
Methods for ascertainment of the primary outcome 
Vital status was determined by clinic report and review of the Social Security Master Death File1.  
Hospitalizations and COPD exacerbations were ascertained by self-report supplemented by medical records 
review.    
 
Randomization process 
The randomization schedule was stratified by regional clinical center with randomly permuted blocks of sizes 2, 4, 
and 6.  The data system generated the treatment assignment only if the electronic checks for conformance with the 
eligibility criteria were passed. 
 
Additional details on sample size calculation 
For the No LTOT group, we assumed a 33% annual hospitalization rate in those with, and a 10% annual 
hospitalization rate in those without, a COPD hospitalization in the prior year, and a 7% annual mortality rate in 
those with, and a 6% rate in those without, a COPD hospitalization in the prior year.  We also assumed that 50% 
of all enrolled patients would have had a COPD hospitalization in the prior year, yielding an estimated 28% 
annual composite event rate.  These assumptions were the consensus of the investigators after reviewing available 
data2-8 and considering differences between the populations studied and the proposed population. We assumed that 
the primary outcome would be obtained on 99% of patients. 
 
Additional details on statistical analysis 
Side-by-side histograms were used to compare the treatment groups on changes from baseline in measured 
outcomes. P-values for the treatment group comparisons on the ranked changes were determined by Wilcoxon 
rank-sum test.  
 
Results are reported as mean ± standard deviation (SD) except where noted.  Bonferroni corrections were used to 
determine the P-value required for statistical significance for secondary and other outcomes,9 as specified in each 
table or figure caption.  Analyses were conducted in SAS (Cary, NC), STATA (College Station, TX), or R 
(https://www.r-project.org/). 
 
Comparison of self-reported oxygen use to measured oxygen use 
All patients randomized to the LTOT group and using stationary oxygen concentrators were asked to report meter 
reading and date read approximately every 2 months for the duration of their follow-up.  Because of problems 
with small dials, inaccessible dials, and change outs from one concentrator to another due to malfunction, 
dissatisfaction or other reason, data were not always available or, if available, not always usable (e.g., date of 
change out provided but starting or ending reading not provided, or reading provided but not the date of the 
reading).  For these reasons, the analysis on self-reported versus measured oxygen usage was limited to 100 
patients using stationary concentrators who were able to provide usable data for at least 4 months (3 usage 
readings); the mean number of usage estimates was 12.5 compared to mean number of self-reports of 10.  The 
analyses presented used all available data during each patient’s follow-up.  The 100 patients included in the 
analysis constitute 27% of the LTOT group and 35% of the 286 stationary concentrator users.  The patients 
included in this adherence analysis were similar to the LTOT patients who were not included in gender, minority 
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status, education level, MMRC score, GOLD COPD score, and exacerbation history.  However, the LTOT 
patients included in this adherence analysis were more likely to have exercise desaturation only and less likely to 
have resting desaturation only than the LTOT patients who were not included.  Figure S2 presents data relating to 
validation of the self-report oxygen usage estimates.   
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Notes:  6MW = 6-minute walk; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity  
 
The Modified Medical Research Council (MMRC) dyspnea score is a single item scale that is completed by the 
patient; the score ranges from 0 to 4, with higher score indicating greater breathlessness. MMRC=0 was 
exclusionary in LOTT10,11. 
 
The Epworth Sleepiness Scale is an 8-item scale that measures general daytime sleepiness and is completed by the 
patient; the total score ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.  Score ≥16 was 
exclusionary in LOTT12.  
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Figure S2.  Validation of self-report oxygen usage estimates.  Usage estimates from stationary concentrator meter 
readings were available for 100 LTOT patients (each patient had at least 2 usage assessments by 
meter reading [at least 3 meter readings] and more than half of the patient’s usage assessments were 
plausible [0-24 hours/day]); 12.5 ± 5.0 assessments per patient).  Panel A is a plot of mean usage 
assessment by concentrator versus the mean self-report of stationary oxygen use (mean of all self-
reports; 10 ± 4.2 reports per patient).  Panel B is a Bland-Altman plot of the difference (self-report – 
meter) versus the mean ([self-report + meter] /2) and shows a significant (P<0.001) linear relationship 
of decreasing difference (and subsequent reversal) with increasing mean. The regression equation 
(standard error) was Y = 3.5(0.7) + 0.3(0.06) * X. The 95% limits of agreement on the slope were ± 
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Figure S3. Kaplan –Meier analyses of secondary outcomes: 
A) Time to first COPD exacerbation (median follow-up of 11.4 months; 114 LTOT patients and 111 No 
LTOT patients were censored as of their date death (if no COPD exacerbation prior to death) or as of the 
date of their last interview (if alive and no COPD exacerbation); 
B) Time to first hospitalization for COPD exacerbation (median follow-up of 24.3 months; 243 LTOT 
patients and 238 No LTOT patients were censored as of their date of death (if no COPD hospitalization 
prior to death) or as of the date of their last interview (if alive and no COPD hospitalization); 
C) Time to first hospitalization for COPD exacerbation or death, whichever came first (median follow-up of 
24.3 months; 201 LTOT patients and 205 No LTOT patients who neither died nor had a COPD 
hospitalization were censored as of the date of their last interview); 
D) Time to first hospitalization for reason other than COPD exacerbation (median follow-up of 18.7 
months; 181 LTOT patients and 179 No LTOT patients were censored as of their date of death (if no non 
COPD hospitalization prior to death) or as of the date of their last interview (if alive and no non COPD 
hospitalization). 
The hazard ratios and 95% confidence limits were calculated from Cox regression models with LTOT (solid 
line) versus No LTOT (dashed line) as the single model variable; P-values were derived from logrank 
tests.  This was an intention-to-treat analysis.  P<0.0125 (0.05/4) was considered statistically significant 
using a Bonferroni adjustment for multiplicity of comparisons9.  
 
A) Time to first COPD exacerbation          
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B) Time to first hospitalization for COPD exacerbation 
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C) Time to first hospitalization for COPD exacerbation or death  
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D) Time to first hospitalization for reason other than COPD exacerbation 
  
12 
LOTT-PrimaryOucomePaper-Appendix.docx  10/4/2016 1:55 PM 
Figure S4.  Histograms of changes from baseline to 4, 12, 16, 24, 36, and 48 months after randomization: 
A) Quality of Well-Being Scale (QWB) mean daily score 
B) St. George’s Respiratory Questionnaire (SGRQ) total score 
C) SF-36 Physical Component Summary (PCS) score 
D) SF-36 Mental Component Summary (MCS) score 
E) Hospital Anxiety and Depression Questionnaire (HADS) anxiety score 
F) HADS depression score 
G) Pittsburgh Sleep Quality Index (PSQI) total score 
H) Post-bronchodilator FEV1 (L) 
I) Room air 6-minute walk distance (feet) 
J) Room air resting oxygen saturation (SpO2, %). 
Analyses are limited to patients whose visit window for the specified follow-up time had closed as of the 
end of the trial.  If the measure was completed, the change in the measure from baseline to the specified 
follow-up time was calculated by subtracting the baseline value from the value at the specified follow-up 
time and the change was then scored from 1 to 10. Except for the QWB, which is anchored in death 
(score for death=0), scores were not imputed for those who had died and deaths are ranked below the 
worst change category. In the analyses including those who were alive and missed the assessment, such 
patients were ranked above the deaths but below the worst change category.  The P-values compare 
LTOT versus No LTOT distributions of changes and were derived from Wilcoxon rank-sum tests on the 
scores.  P-values labeled “without missing” exclude the patients who were alive and missed the 
assessment; P-values labeled “with missing” include the patients who were alive and missed the 
assessment (shown in the bar labeled “missing”).  Readers should interpret the P-values with caution 
since the difference between the treatment groups in the proportion missing may make a “with missing” 
P-value statistically significant.  The degree to which the distribution is shifted to the upper right of the 
chart indicates the degree of relative benefit of LTOT over No LTOT. This is an intention-to-treat 
analysis. 
 
A)  Change in Quality of Well-Being Scale (QWB) mean daily score (range 0-1, higher score indicates better quality 
of life, MID=0.03)13,14.  P<0.008 (0.05/6 time points) was considered statistically significant using a Bonferroni 
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B) Change in St George’s Respiratory Questionnaire (SGRQ) total score (range 0-100, higher score indicates worse 
better health-related quality of life, MID=4)15,16.  P<0.008 (0.05/6 time points) was considered statistically 
significant using a Bonferroni adjustment for multiplicity of comparisons9. 
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C) Change in SF-36 Physical Component Summary score (range 0-100, higher score indicates better function, 
MID=5)17.  P<0.0125 (0.05/4 time points) was considered statistically significant using a Bonferroni adjustment for 
multiplicity of comparisons9.   
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D) Change in SF-36 Mental Component Summary score (range 0-100, higher score indicates better function, 
MID=5)17.  P<0.0125 (0.05/4 time points) was considered statistically significant using a Bonferroni adjustment for 
multiplicity of comparisons9.   
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E) Change in Hospital Anxiety and Depression Scale (HADS) anxiety score (range 0-21, higher score indicates 
greater anxiety, MID=1.5)18,19.  P<0.0125 (0.05/4 time points) was considered statistically significant using a 
Bonferroni adjustment for multiplicity of comparisons9.   
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F) Change in Hospital Anxiety and Depression Scale (HADS) depression score (range 0-21, higher score indicates 
greater depression, MID=1.5)18,19.  P<0.0125 (0.05/4 time points) was considered statistically significant using a 
Bonferroni adjustment for multiplicity of comparisons9.   
18 
LOTT-PrimaryOucomePaper-Appendix.docx  10/4/2016 1:55 PM 
G) Change in Pittsburgh Sleep Quality Index (PSQI) total score (range 0-21, higher score indicates worse sleep 
quality)20.  P<0.0125 (0.05/4 time points) was considered statistically significant using a Bonferroni adjustment for 
multiplicity of comparisons9.   
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H) Change in post-bronchodilator FEV1 (L).  P<0.0125 (0.05/4 time points) was considered statistically significant 
using a Bonferroni adjustment for multiplicity of comparisons9.  
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I) Change in room air 6-minute walk distance (feet).  P<0.0125 (0.05/4 time points) was considered statistically 
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J) Change in room air resting oxygen saturation (SpO2, %).  P<0.0125 (0.05/4 time points) was considered 
statistically significant using a Bonferroni adjustment for multiplicity of comparisons9.
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Table S1.  Patient selection criteria 
  
 
Inclusion (all must be met) 
 COPD-dominated lung disease 
 Age at least 40 years 
 At least 10 pack-years cigarette smoking history 
 Modified Medical Research Council (MMRC)* dyspnea score ≥ 1 (short of breath when hurrying on 
the level or walking up a slight hill) 
 Post-bronchodilator FEV1 / FVC < 0.70 
 Post-bronchodilator FEV1 <70% of the predicted normal value or > 70% of the predicted normal 
value and Study Physician determines that there is radiologic evidence of emphysema 
 Resting SpO2 89-93% (moderate resting hypoxemia) OR resting SpO2 94% or greater and 
desaturation during exercise defined as SpO2 below 90% for at least 10 seconds during the 6-minute 
walk test (normal resting saturation but hypoxemia with exercise) 
 Medicare Part A and Part B beneficiary, insurance willing to pay costs of treatment and costs of 
study procedures and visits, or willing to self-pay costs 
 Approval by study physician for randomization to either treatment group 
 No exacerbation requiring antibiotics or new/ increased dose of systemic corticosteroids in the 30 
days prior to screening 
 At least 30 days post-discharge from an acute care hospital for COPD or other condition prior to 
screening 
 If patient regularly uses supplemental oxygen prior to screening, all of the following must be met 
before randomization: 
- Patient agrees to stop using supplemental oxygen if randomized to no supplemental oxygen 
- Patient’s physician agrees in writing to rescind order for supplemental oxygen if patient is 
randomized to no supplemental oxygen 
- Patient must not use supplemental oxygen for the 4 calendar days prior to randomization and must 
report that he/she had no problems doing without the oxygen 
 Signature of written contract agreeing not to smoke while using supplemental oxygen 
 
Exclusion (none may be met) 
 COPD exacerbation requiring antibiotics, new or increased dose of systemic corticosteroids, or 
oxygen treatment after screening starts and prior to randomization (chronic use of corticosteroids 
while health is stable is not exclusionary) 
 New prescription of supplemental oxygen after screening starts and before randomization 
 Thoracic surgery or other procedure in the 6 months prior to evaluation likely to cause instability of 
pulmonary status 
 Non-COPD lung disease that would affect oxygenation or survival 
 Epworth Sleepiness Scale† score greater than 15 
 Desaturation below 80% for at least 1 minute during the 6-minute walk 
 Disease or condition expected to cause death or inability to perform procedures for the trial or 
inability to comply with therapy within 6 months of randomization, as judged by study physician 
 Participation in another intervention study 
 
COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity. 
*The Modified Medical Research Council (MMRC) dyspnea score is a single item scale that is completed by the patient; the score ranges from 0 to 4, 
with higher score indicating greater breathlessness10,11. MMRC=0 was exclusionary in LOTT. 
†The Epworth Sleepiness Scale is an 8-item scale that measures general daytime sleepiness and is completed by the patient; the total score ranges 
from 0 to 24, with higher scores indicating greater daytime sleepiness12.  Score ≥16 was exclusionary in LOTT.  
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Table S2.  Data collection schedule 
Notes:  BL = baseline; RZ = randomization; C=clinic; T=telephone; M=mail; 6MW=6 minute walk; FEV1 = forced expiratory volume in one second; FVC = 
forced vital capacity; MMRC = Modified Medical Research Council. 
*Years 4, 5, and 6 follow the same pattern of data collection. 
† Table does not show adherence contact schedule. 
‡ For participants randomized to supplemental oxygen. 
§The MMRC dyspnea scale is a single item scale that is completed by the patient; the score ranges from 0 to 4, with higher score indicating greater 
breathlessness10,11. MMRC=0 was exclusionary in LOTT. 
¶The Epworth Sleepiness Scale is an 8-item scale that measures general daytime sleepiness and is completed by the patient; the total score ranges from 0 to 24, 
with higher scores indicating greater daytime sleepiness12.  Score ≥16 was exclusionary in LOTT. 
ǁThe Quality of Well Being scale is a 77-item quality of life questionnaire completed by the patient.  The scoring is anchored in death (score 0).  The average daily 
score ranges from 0 to 1, with higher scores indicating better quality of life; Minimum Important Difference (MID)=0.0313,14. 
**The St. George’s Respiratory Questionnaire is a 51-item questionnaire on the health-related quality of life with regard to respiratory symptoms that is completed 
by the patient; the total score ranges from 0 to 100, with higher scores indicating worse health-related qualify of life; MID=415,16. 
 ††The SF-36 is a 36-item quality of life scale that is completed by the patient.  The Physical Component Summary (PCS) score ranges from 0 to 100, with higher 
scores indicating better function; MID=5.  The Mental Component Summary (MCS) score ranges from 0 to 100, with higher scores indicating better function; 
MID=517. 
‡‡The Hospital Anxiety and Depression Scale (HADS) is a 14-item scale that is completed by the patient.  The anxiety score ranges from 0 to 21, with higher 
scores indicating greater anxiety; MID=1.5 and the depression score ranges from 0 to 21, with higher scores indicating greater depression; MID=1.518,19. 
§§Pittsburgh Sleep Quality Index (PSQI) is a 24-item scale completed by the patient and partner.  The total score ranges 0-21, with higher scores indicating worse 
sleep quality20.  
  Follow-up 
 BL RZ Year 1 Year 2 Year 3* 
Months from randomization -2 0 4 8 12 16 20 24 28 32 36 
Type of visit† C C T,M T C T,M T C T T C 
Core (all participants, all sites)  
History X X X X X X X X X X X 
Room air resting oximetry X    X   X   X 
Room air 6MW with oximetry X    X   X   X 
Ambulatory dosing‡  X   X   X   X 
FEV1, FVC X           
Height X           
Weight and pretibial pitting edema X    X   X   X 
Hemoglobin and hematocrit X           
Cotinine (if not using nicotine products) X    X       
MMRC dyspnea scale§ X    X   X   X 
Epworth Sleepiness Scale¶ X           
Quality of Well-Being Scaleǁ X  M  X M  X   X 
St. George’s Respiratory Questionnaire** X  M  X M  X   X 
Expanded (participants at selected sites) 
SF-36 quality of life scale†† X    X   X   X 
Hospital Anxiety and Depression Scale‡‡ X    X   X   X 
Pittsburgh Sleep Quality Index§§ X    X   X   X 
FEV1, FVC     X   X   X 
Alpha 1-antitrypsin level and phenotype X           
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Table S3.  Screening and randomization by clinical center 
Regional 
Clinical 












Brigham and Women’s 
Hospital Brigham and Women’s Hospital 25 5 48 
 Boston VA 75 25  
 Boston Medical Center 40 18  
     
Cleveland Clinic Cleveland Clinic 58 33 42 
 University Hospitals 4 1  
 Valley Care Health 2 0  
 Crouse Medical 5 4  
 Cleveland Clinic Weston, Florida 13 4  
     
Denver Health Denver Health 0 0 6 
 National Jewish 8 4  
 University of Colorado 4 2  
 University of Iowa 2 0  
     
Duke University Duke University 45 28 28 
     
Kaiser Foundation Kaiser Foundation 67 9 9 
     
Los Angeles Biomedical 
Research Institute Los Angeles Biomedical Research Institute 21 8 55 
 Loma Linda VA 98 44  
 City of Hope 7 3  
     
Ohio State University Ohio State University 101 47 97 
 Cincinnati VA 115 50  
 University of Kentucky 8 0  
     
Temple University Temple University 108 63 139 
 Geisinger Health System 42 11  
 Louisiana State University 6 2  
 Institute for Respiratory and Sleep Medicine 71 45  
 University of Maryland 8 5  
 Buffalo VA 27 8  
 Respiratory Specialists 13 5  
     
University of Alabama at 
Birmingham University of Alabama at Birmingham 72 33 84 
 Birmingham VA 79 35  
 North Florida/South Georgia VA 30 16  
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Regional 
Clinical 












University of Michigan University of Michigan 75 22 43 
 Beaumont Hospital 29 6  
 Henry Ford Hospital 6 2  
 Ann Arbor VA 2 0  
 San Antonio VA 37 13  
 Spectrum Health 2 0  
     
University of Pittsburgh University of Pittsburgh 38 21 22 
 Pulmonary Partners 1 1  
     
University of Utah University of Utah 140 40 40 
     
University of Washington University of Washington 13 4 71 
 Puget Sound VA 157 66  
 Harborview 1 1  
     
Washington University Washington University 52 24 54 
 Christian Hospital 15 8  
 University of Illinois at Chicago 4 2  
 Suburban Lung Associates 6 4  
 Central Florida Pulmonary Group 3 1  
 University of California, San Diego 24 15  
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Demographic   
Age (years) 69.3 ± 7.4 68.3 ± 7.5 
  
Male 276 (75%) 266 (72%)
  
Hispanic ethnicity 4 ( 1%) 10 ( 3%)
  
Race†  
African American 34 (  9%) 46 (12%)
Caucasian 328 (89%) 311 (85%)
Other 11 (  3%) 17 (  5%)
  
Married or widowed 236 (64%) 234 (64%)
  
Medicare coverage 273 (74%) 268 (73%)
  
Enrolled at Veterans Administration site 129 (35%) 128 (35%)
  
Clinical  
Pack-years of tobacco cigarette smoking 60.8 ± 31.1 62.0 ± 34.7 
Missing, n 4 0 
  
Current tobacco cigarette smoker 92 (25%) 110 (30%)
  
Body mass index (kg/m2) 28.3 ± 6.5 28.9 ± 6.5 
  
Ever used home oxygen 113 (31%) 107 (29%)
  
Currently using home oxygen 59 (16%) 55 (15%)
  
COPD exacerbation in 3 months prior to screening 75 (20%) 63 (17%)
  
Hospitalized for COPD exacerbation in year prior to screening‡ 28 ( 8%) 35 (11%)
Missing, n 39 41 
  
Symptoms/health status  
Quality of Well-Being Scale mean daily score§ 0.56 ± 0.13 0.56 ± 0.13 
   
St. George’s Respiratory Questionnaire total score¶ 50.2 ± 17.1 49.8 ± 18.7 
  
Modified Medical Research Council dyspnea scoreǁ  
1 103 (28%) 97 (26%)
2 101 (27%) 114 (31%)
3 132 (36%) 136 (37%)
4 34 ( 9%) 21 ( 6%)
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Epworth Sleepiness Scale total score**  
0-5 173 (47%) 157 (43%)
6-10 143 (39%) 137 (37%)
11-15 53 (14%) 72 (20%)
> 15 1 (<1%) 2 (  1%)
  
Physiology  
Oxygen desaturation type qualifying patient for enrollment  
Resting only  60 (16%) 73 (20%)
Exercise only 171 (46%) 148 (40%)
Resting and exercise 139 (38%) 147 (40%)
  
Room air SpO2 at rest (%)   
All 93.5 ± 1.9 93.3 ± 2.1
Resting only  92.3 ± 0.8 92.4 ± 0.9
Exercise only 95.2 ± 1.2 95.4 ± 1.4
Resting and exercise 91.9 ± 1.2 91.7 ± 1.1
  
Room air nadir SpO2 during 6-minute walk (%)††  
< 86 85 (29%) 86 (29%)
86-88 103 (36%) 105 (36%)
> 88 102 (35%) 101 (35%)
Missing, n††  80 76 
  
GOLD lung function category  
FEV1/FVC ≥ 0.7 4 (  1%) 4 (  1%)
I 12 (  3%) 12 (  3%)
II 110 (30%) 128 (35%)
III 180 (49%) 176 (48%)
IV 64 (17%) 47 (13%)
Missing, n  0 1 
  
Post bronchodilator FEV1 percent predicted (%) 46 ± 17 47 ± 16 
Missing, n  0 1 
   
Post bronchodilator FVC percent predicted (%) 75 ± 19 77 ± 20 
Missing, n  0 1 
   
Post bronchodilator FEV1/FVC ratio  0.46 ± 0.12 0.47 ± 0.13 
Missing, n  0 1 
  
Distance walked in 6 minutes (feet)‡‡ 1027 ± 337 1062 ± 313 
Missing, n  4 6 
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Co-morbid conditions (self-reported)  
Anemia 56 (15%) 64 (17%)
Cardiovascular disease§§ 114 (31%) 121 (33%)
Depression 128 (35%) 126 (34%)
GERD or stomach ulcer 160 (43%) 163 (44%)
Hypertension 233 (63%) 221 (60%)
Sleep apnea 82 (22%) 83 (23%)
  Using continuous positive airway pressure device for sleep apnea 52 (63%) 59 (71%)
  
BODE¶¶  
0-2 77 (21%) 87 (24%)
3-4 123 (33%) 155 (42%)
5-6 126 (34%) 87 (24%)
7-10 40 (11%) 33 (  9%)
Mean ± SD 4.2 ± 2.0 3.9 ± 1.8 
Missing, n 4 6 
*Plus-minus values are observed mean ± SD.  The two treatment groups were similar on characteristics except for the BODE index, which tended to 
be lower in the LTOT group compared to the No LTOT group ((P=0.007 for difference in categorized distribution; P=0.02 for difference in means).    
GOLD denotes Global initiative for chronic Obstructive Lung Disease; FEV1 denotes forced expiratory volume in 1 second; FVC denotes forced vital 
capacity. 
†Patient may select more than one race group. 
§The Quality of Well Being scale is a 77-item quality of life questionnaire completed by the patient.  The scoring is anchored in death (score 0).  The 
average daily score ranges from 0 to 1, with higher scores indicating better quality of life. Minimum Important Difference (MID)=0.0313,14 
¶The St. George’s Respiratory Questionnaire is a 51-item questionnaire on the health-related quality of life with regard to respiratory symptoms that 
is completed by the patient; the total score ranges from 0 to 100, with higher scores indicating worse health-related qualify of life.  MID=415,16. 
ǁThe Modified Medical Research Council Dyspnea Score is a single item scale that is completed by the patient; the score ranges from 0 to 4, with 
higher score indicating greater breathlessness10,11. MMRC=0 was exclusionary in LOTT. 
**The Epworth Sleepiness Scale is an 8-item scale that measures general daytime sleepiness and is completed by the patient; the total score ranges 
from 0 to 24, with higher scores indicating greater daytime sleepiness12.  Score ≥16 was exclusionary in LOTT.  
††Nadir SpO2 is the 10th lowest SpO2 observed during the 6-minute walk.  10 patients did not complete the 6-minute walk; nadir SpO2 could not be 
calculated for 146 patients due to loss or a technical issue with their enrollment oximetry data file.  
‡‡10 patients did not complete the 6-minute walk at baseline due to leg amputation (2), arthritis, neuropathy, use of a wheelchair (3), peripheral artery 
disease, sciatica, and shortness of breath. To convert feet to meters, divide by 3.28. 
§§Cardiovascular disease includes angina, coronary artery disease, coronary artery revascularization, myocardial infarction, heart failure, and 
congestive heart failure 
¶¶ The BODE index is a scoring system incorporating body mass index, airflow obstruction (post bronchodilator FEV1 percent predicted), dyspnea 
(MMRC score), and exercise (6-minute walk distance); higher score indicates greater risk of mortality21.  
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Table S5.  Supplemental oxygen flow setting prescribed to LTOT patients (N=368) for ambulation. 
 











Median 2 2 2 2 2 
(25th %-tile, 75th %-tile)  (2, 2) (2, 2) (2, 3) (2, 3) (2, 3) 
(10th %-tile, 90th %-tile) (2, 3) (2, 4) (2, 4) (2, 4) (2, 4) 
No. of patients with data 357 286 218 165 105 
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Table S6.  Primary outcome (time to death or first hospitalization, whichever comes first) for those 
randomized to LTOT versus those randomized to No LTOT in subgroups of patients defined at 
baseline.  This is an intention-to-treat analysis.  P<0.0007 (0.01/14) was considered statistically 
significant using a Bonferroni adjustment for multiple comparisons9. 
 
 N Events 
Rate/ 
100 p-y HR (95% CI) P* 
Interaction 
P† 
       
All patients       
No LTOT 370 250 36.4 1.0   
LTOT 368 248 34.2 0.94 (0.79, 1.12) 0.52  
       
LTOT prescription type       
No LTOT 370 250 36.4 1.0  
 0.18 LTOT during sleep and exercise 148 102 37.9 1.05 (0.83, 1.32) 0.68 
24-hour LTOT 220 146 32.1 0.88 (0.72, 1.08) 0.23 
       
Desaturation qualifying for LOTT       
At rest only      
0.99 
No LTOT 60 38 34.4 1.0  
LTOT 73 50 32.6 0.96 (0.63, 1.47) 0.86 
On exercise only      
No LTOT 171 119 39.3 1.0  
LTOT 148 102 37.9 0.95 (0.73, 1.24) 0.71 
At rest and on exercise      
No LTOT 139 93 34.0 1.0  
LTOT 147 96 31.8 0.95 (0.72, 1.27) 0.74 
       
Age (years)       
65-70      
0.03 
No LTOT 211 132 31.7 1.0  
LTOT 238 162 35.3 1.11 (0.88, 1.40) 0.38 
71 or older      
No LTOT 159 118 43.6 1.0  
LTOT 130 86 32.4 0.75 (0.57, 0.99) 0.04 
       
Race       
Minority      
0.77 
No LTOT 41 30 44.2 1.0  
LTOT 55 41 38.8 0.86 (0.53, 1.37) 0.52 
White      
No LTOT 328 219 35.5 1.0  
LTOT 311 206 33.6 0.95 (0.78, 1.15) 0.58 
       
Gender       
Male      
0.15 
No LTOT 276 190 39.1 1.0  
LTOT 266 178 33.9 0.87 (0.71, 1.07) 0.19 
Female      
No LTOT 94 60 29.9 1.0  
LTOT 102 70 35.1 1.15 (0.82, 1.63) 0.42 
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 N Events 
Rate/ 
100 p-y HR (95% CI) P* 
Interaction 
P† 
       
Current cigarette smoker       
Yes      
0.81 
No LTOT 92 64 39.9 1.0  
LTOT 110 77 38.6 0.96 (0.69, 1.33) 0.79 
No      
No LTOT 278 186 35.4 1.0  
LTOT 258 171 32.6 0.93 (0.75, 1.14) 0.47 
       
COPD exacerbation in 3 months 
prior to enrollment  
     
Yes      
0.007 
No LTOT 75 57 51.1 1.0  
LTOT 63 38 28.9 0.58 (0.39, 0.88) 0.01 
No      
No LTOT 295 193 33.6 1.0  
LTOT 305 210 35.4 1.07 (0.88, 1.30) 0.52 
       
Nadir SpO2 during 6-minute walk‡       
< 86%      
0.62 
No LTOT 85 53 31.8 1.0  
LTOT 86 53 33.5 1.10 (0.75, 1.63) 0.62 
86% - 88%      
No LTOT 103 69 37.9 1.0  
LTOT 105 69 35.0 0.92 (0.66, 1.28) 0.62 
> 88%      
No LTOT 102 71 42.4 1.0  
LTOT 101 70 36.6 0.88 (0.63, 1.23) 0.45 
       
Pre bronchodilator FEV1       
< 41% predicted      
0.60 
No LTOT 168 115 39.2 1.0  
LTOT 169 121 35.9 0.93 (0.72, 1.20) 0.55 
≥ 41 predicted      
No LTOT 162 107 32.4 1.0  
LTOT 179 114 32.9 1.00 (0.77, 1.31) 0.97 
       
BODE score§       
0-4      
0.16 
No LTOT 200 122 28.8 1.0  
LTOT 242 153 31.0 1.08 (0.85, 1.37) 0.53 
5-10      
No LTOT 166 127 49.4 1.0  
LTOT 120 91 41.3 0.84 (0.64, 1.11) 0.22 
       
 32 
LOTT-PrimaryOucomePaper-Appendix.docx  10/4/2016 1:55 PM 
 N Events 
Rate/ 
100 p-y HR (95% CI) P* 
Interaction 
P† 
       
QWB mean daily score¶       
< 0.55 (below median)      
0.03 
No LTOT 185 132 44.2 1.0  
LTOT 177 120 33.9 0.77 (0.60, 0.99) 0.04 
≥ 0.55 (at or above median)      
No LTOT 185 118 30.4 1.0  
LTOT 191 128 34.6 1.15 (0.89, 1.48) 0.28 
       
SF-36 PCS score§       
< 33 (below median)      
0.42 
No LTOT 148 98 39.0 1.0  
LTOT 158 108 34.7 0.90 (0.68, 1.18) 0.45 
≥ 33 (at or above median)      
No LTOT 154 104 32.4 1.0  
LTOT 156 105 34.1 1.08 (0.82, 1.42) 0.58 
       
Body mass index (kg/m2)       
< 25.1      
0.94 
No LTOT 135 98 43.1 1.0  
LTOT 109 77 35.1 0.82 (0.61, 1.11) 0.21 
25.1 – 30.8      
No LTOT 116 72 30.1 1.0  
LTOT 133 92 38.5 1.28 (0.94, 1.75) 0.12 
>30.8      
No LTOT 119 80 36.3 1.0  
LTOT 126 79 29.7 0.82 (0.60, 1.12) 0.21 
       
History of anemia       
Yes      
0.70 
No LTOT 56 42 41.3 1.0  
LTOT 64 46 42.0 1.0 (0.66, 1.53) >0.99 
No      
No LTOT 314 208 35.6 1.0  
LTOT 304 202 32.9 0.93 (0.76, 1.12) 0.43 
       
*Logrank test for difference in the primary outcome between groups within the specified stratum. 
†P-value for Wald chi square test of interaction between treatment group and subgrouping factor on the primary outcome, except for oxygen 
prescription groups, where the P-value tests for difference between patients prescribed oxygen during sleep and exercise versus those 
prescribed 24-hour oxygen. 
‡Nadir SpO2 is the 10th lowest SpO2 observed during the 6-minute walk.  Data from oximetry during the 6-minute walk could not be analyzed for 
146 patients; 10 patients did not complete the 6-minute walk. 
§The BODE index is a scoring system incorporating body mass index, airflow obstruction (post bronchodilator FEV1 percent predicted), dyspnea 
(MMRC score), and exercise (6-minute walk distance); higher score indicates greater risk of mortality21. 
¶The Quality of Well Being scale is a 77-item quality of life questionnaire completed by the patient.  The scoring is anchored in death (score 0).  
The average daily score ranges from 0 to 1, with higher scores indicating better quality of life. Minimum Important Difference 
(MID)=0.0313,14. 
§ The SF-36 is a 36-item quality of life scale that is completed by the patient.  The Physical Component Summary (PCS) score ranges from 0 to 
100, with higher scores indicating better function; MID=517.  
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Table S7.  Time to death or first hospitalization, whichever occurred first, for those reporting supplemental 
oxygen use versus those reporting not using supplemental oxygen.  This is an as treated analysis.  
P<0.025 (0.05/2) was considered statistically significant using a Bonferroni adjustment for 
multiplicity of comparisons9. 
 








Using supplemental oxygen includes patients: 
- Randomized to 24-hour oxygen and reporting use 
of at least 16 hours per day averaged over 
follow-up 
- Randomized to oxygen during sleep and exercise 
and reporting use of at least 8 hours per day 
averaged over follow-up 
- Randomized to no oxygen and reporting use of  at 
least 8 hours per day averaged over follow-up 







No. of patients 496 242 
No. of events 328 170 
Rate per 100 person-years 35.2 35.6 
Hazard ratio (Using versus Not using) 1.02 




Using includes patients: 
- Randomized to 24-hour oxygen and reporting use 
of at least 16 hours per day averaged over 
follow-up 
- Randomized to oxygen during sleep and exercise 
and reporting use of at least 16 hours per day 
averaged over follow-up 
- Randomized to no oxygen and reporting use of at 
least 16 hours per day averaged over follow-up 
Not using includes all other patients 
 
  
No. of patients 604 134 
No. of events 405 93 
Rate per 100 person-years 35.1 36.1 
Hazard ratio (Using vs. Not using) 1.03 
(95% CI) (0.82, 1.29) 
P* 0.80 
Notes:  
 CI denotes confidence interval. 
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Table S8.  Comparison of LOTT design assumptions to observed data 
*By 2012, it had become evident that the treatment group crossover rates assumed when the trial was 
designed (originally 21%, No LTOT receiving oxygen treatment; 50% LTOT stopping oxygen treatment) 
were much greater than the observed crossover rates; therefore, in March 2012, the LOTT DSMB approved a 
revised sample size calculation of 737 patients based on the crossover rates observed to that date, 11.7%, No 





   
Crossover rates   
Overall % of No LTOT group receiving oxygen treatment 11.7%* 8.7% 
(6.6, 11.2) 
Overall % of LTOT group stopping oxygen treatment  3.1%* 2.2% 
(1.3, 3.6) 
   
Event rates   
Composite event rate in No LTOT group 28% 36.4% 
(32.0, 41.2) 
Hospitalizations/yr in those with recent COPD exacerbation 33% 73.1 
(46.8, 108.7) 
Hospitalization/yr in those without recent COPD exacerbation 10% 32.2 
(27.7, 37.3) 
Mortality in those with a recent COPD exacerbation 7% 5.3% 
(1.7, 12.2) 
Mortality in those without a recent COPD exacerbation 6% 5.6% 
(4.2, 7.3) 
   
Population composition at trial entry    
Patients with recent COPD hospitalization 50% 9.6% 
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Table S9.  Frequency and rate of hospitalization, COPD exacerbation, hospitalization for COPD 
exacerbation, and hospitalization for other than COPD exacerbation.  This is an intention-to-treat 
analysis.  P<0.0125 (0.05/4) was considered statistically significant using a Bonferroni 
adjustment for multiplicity of comparisons9. 
 




All cause hospitalization    
Patients with no hospitalization 36% 38% 0.77 
Patients with exactly 1 hospitalization 24% 22%  
Patients with 2 or more hospitalizations 40% 40%  
    
Total number of hospitalizations 651 685  




(0.91, 1.13) 0.81 
    
COPD exacerbation    
Patients with no COPD exacerbation 35% 34% 0.91 
Patients with exactly 1 COPD exacerbation 22% 22%  
Patients with 2 or more COPD exacerbations 43% 45%  
    
Total number of COPD exacerbations 785 880  




(0.98, 1.19) 0.12 
    
Hospitalization for COPD exacerbation    
Patients without hospitalization for COPD exacerbation 64% 66% 0.83 
Patients with exactly 1 hospitalization for COPD exacerbation 21% 20%  
Patients with 2 or more hospitalizations for COPD exacerbation 14% 14%  
    
Total number of hospitalizations for COPD exacerbation 259 265  




(0.83, 1.17) 0.86 
    
Hospitalization for other than COPD exacerbation    
Patients without hospitalization for other than COPD exacerbation 48% 49% 0.24 
Patients with exactly 1 hospitalization for other than COPD exacerbation 26% 21%  
Patients with 2 or more hospitalizations for other than COPD exacerbation 25% 29%  
    
Total number of hospitalizations for other than COPD exacerbation 392 420  




(0.90, 1.18) 0.66 
Notes:  
CI denotes confidence interval. 
For time to event analysis, living patients who do not have the event are censored as of their last interview; deceased patients who did 
not have the event prior to death are censored as of their date of death. 
*Fisher’s exact test for difference in frequency distribution or difference in rate ratio.
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Table S10.  Changes from baseline to 4, 12, 16, 24, 36, and 48 months after randomization in Quality of Well-Being Scale (QWB) mean daily score, St. 
George’s Respiratory Questionnaire (SGRQ) total score, SF-36 Physical Component Summary (PCS) score, SF-36 Mental Component Summary 
(MCS) score, Hospital Anxiety and Depression Questionnaire (HADS) anxiety score, HADS depression score,  Pittsburgh Sleep Quality Index 
(PSQI) total score, post-bronchodilator FEV1 (L), room air 6-minute walk distance (feet), and room air resting oxygen saturation (SpO2, %), and 
development of severe resting and exercise desaturation during follow-up, those randomized to LTOT group versus those randomized to No LTOT.  
Analyses are limited to patients whose visit window for the specified follow-up time had closed as of the end of the trial.  Changes were calculated 
by subtracting the baseline value from the value at the specified follow-up time.  For the QWB, patients who died were assigned a score of 0 on the 
questionnaire for that follow-up time.  This is an intention-to-treat analysis. 
 
  




























                  
Quality of Well-Being Scale mean daily score*              
No. of patients                  
Missed and alive 50 52  48 18  69 63  42 29  34 15  32 19 
In analysis 320 316  312 341  269 274  268 276  206 229  149 158 
BL, mean 0.56 0.56  0.56 0.55  0.56 0.56  0.56 0.56  0.57 0.56  0.57 0.56 
Chg. from BL, 





P†, within group  0.02 0.01  <0.001 0.01  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001
P†, between 





                  
St. George’s Respiratory Questionnaire, total score§             
No. of patients                  
Missed or dead 52 54  61 28  86 79  67 53  78 51  67 55 
In analysis 318 314  299 331  252 258  243 252  162 193  114 122 
BL, mean 49.5 49.1  48.3 49.7  48.6 48.8  48.4 48.8  46.9 49.0  46.5 50.0 
Chg. from BL, 





P†, within group 0.33 0.007  0.66 0.12  0.14 0.76  0.14 0.43  0.33 0.33  0.34 0.20 
P†, between 
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SF-36, Physical Component Summary score¶           
No. of patientsǁ                  
Missed or dead    45 17     47 31  43 21  54 36 
In analysis    241 279     197 214  133 169  94 105 
BL, mean    34.6 33.8     34.8 34.0  36.2 34.0  36.4 33.3 
Chg. from BL, 





P† within group    0.03 0.30     0.46 0.46  <0.001 0.22  0.17 0.17 
P†, between 





              
SF-36, Mental Component Summary score¶           
No. of patientsǁ                  
Missed or dead    45 17     47 31  43 21  54 36 
In analysis    241 279     197 214  133 169  94 105 
BL, mean    51.7 50.2     52.3 51.1  52.5 51.2  52.1 51.8 
Chg. from BL, 





P†, within group    0.02 0.12     <0.001 <0.001  0.09 <0.001  0.02 <0.001
P†, between 
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HADS anxiety score††             
No. of patientsǁ                  
Missed or dead    43 16     47 31  43 21  53 35 
In analysis    243 280     197 214  133 169  94 106 
BL, mean    5.1 6.2     5.0 6.0  5.1 5.9  5.1 5.7 
Chg. from BL, 





P†, within group    0.20 0.36     0.02 0.62  0.27 0.42  0.99 0.17 
P†, between 





              
HADS depression score††             
No. of patientsǁ                  
Missed or dead    43 16     47 31  44 21  53 34 
In analysis    243 280     197 214  132 169  94 107 
BL, mean    4.9 5.4     4.6 5.1  4.3 4.9  4.6 5.1 
Chg. from BL, 





P†, within group    <0.001 0.02     <0.001 0.005  0.01 <0.001  0.02 <0.001
P†, between 
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Pittsburgh Sleep Quality Index total score‡‡           
No. of patientsǁ                  
Missed or dead    46 22     47 32  42 22  54 37 
In analysis    240 274     197 213  134 168  93 104 
BL, mean    7.4 8.0     7.3 7.9  7.0 7.8  6.8 7.7 
Chg. from BL, 





P†, within group    0.09 0.05     0.53 0.53  0.23 0.98  0.20 0.47 
P†, between 





              
Post-bronchodilator FEV1 (L)             
No. of patientsǁ                  
Missed or dead    63 28     69 43  61 40  70 42 
In analysis    223 268     174 202  115 149  77 99 
BL, mean    1.4 1.3     1.4 1.3  1.4 1.3  1.4 1.3 
Chg. from BL, 





P†, within group    0.009 0.08     <0.001 <0.001  <0.001 <0.001  <0.001 <0.001
P†, between 
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Room air 6-minute walk distance (feet)             
No. of patients                  
Missed or dead    93 68     109 82  109 82  97 70 
In analysis    267 291     201 223  131 162  84 107 
BL, mean    1057 1075     1074 1101  1128 1126  1119 1150 
Chg. from BL, 





P†, within group    <0.001 0.001     <0.001 <0.001  <0.001 <0.001  <0.001 <0.001
P†, between 





              
Room air resting oxygen saturation (%)             
No. of patients                  
Missed or dead    72 37     85 59  96 60  81 60 
In analysis    288 322     225 246  144 184  100 117 
BL, mean    93.5 93.3     93.5 93.3  93.3 93.5  93.5 93.4 
Chg. from BL, 





P†, within group    0.19 0.05     0.03 0.92  0.95 0.32  0.62 0.56 
P†, between 
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Development of severe resting desaturation§§           
No. of patients                  
Missed or dead    72 37     85 59  96 60  81 60 
In analysis    288 322     225 246  144 184  100 117 
No. (%) with severe 
resting 




















RR for developing 
severe resting 





95% CI   (0.54, 8.00)    (0.37, 2.26)  (0.54, 3.79)  (0.22, 3.33) 
P¶¶, **   0.35    >0.99  0.62  >0.99 
              
Development of severe exercise desaturationǁǁ         
No. of patients                  
Missed or dead    80 48     95 70  102 75  90 64 
In analysis    280 311     215 235  138 169  91 113 
No. (%) with severe 
exercise 



















RR for developing 
severe exercise 





95% CI   (0.36, 1.64)    (0.47, 2.05)  (0.46, 2.71)  (0.23, 0.98) 
P¶¶, **   0.55    >0.99  >0.99  0.06 
BL = baseline; Chg. = change; RR = relative risk, LTOT versus No LTOT; CI = confidence interval; HADS = Hospital Anxiety and Depression Scale; FEV1 = forced expiratory volume in 1 second 
 
*The Quality of Well Being scale is a 77-item quality of life questionnaire completed by the patient.  The scoring is anchored in death (score 0).  The average daily score ranges from 0 to 1, with higher scores indicating 
better quality of life; Minimum Important Difference (MID)=0.0313,14. 
†P-value for t-test 
‡P<0.008 (0.05/6 time points) was considered statistically significant using a Bonferroni adjustment for multiplicity of comparisons9. 
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§The St. George’s Respiratory Questionnaire is a 51-item questionnaire on the health-related quality of life with regard to respiratory symptoms that is completed by the patient; the total score ranges from 0 to 100, with 
higher scores indicating worse health-related qualify of life; MID=415,16. 
¶The SF-36 is a 36-item quality of life scale that is completed by the patient.  The Physical Component Summary (PCS) score ranges from 0 to 100, with higher scores indicating better function; MID=5.  The Mental 
Component Summary (MCS) score ranges from 0 to 100, with higher scores indicating better function; MID=517. 
ǁThe SF-36, HADS, and PSQI questionnaires at all time points and spirometry in follow-up were completed at a subset of 33 sites; 82% of all No LTOT patients and 85% of all LTOT patients enrolled at these sites. 
**P<0.0125 (0.05/4 time points) was considered statistically significant using a Bonferroni adjustment for multiplicity of comparisons9. 
††The Hospital Anxiety and Depression Scale (HADS) is a 14-item scale that is completed by the patient.  The anxiety score ranges from 0 to 21, with higher scores indicating greater anxiety; MID=1.5. The depression 
score ranges from 0 to 21, with higher scores indicating greater depression; MID=1.518,19. 
‡‡Pittsburgh Sleep Quality Index (PSQI) is a 24-item scale completed by the patient and partner.  The total score ranges 0-21, with higher scores indicating worse sleep quality20. 
§§Severe resting desaturation is defined as saturation below 89% during room air resting saturation test.  
¶¶P-value for Fisher’s exact test 
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Table S11. Adverse events reported to be possibly, probably or definitely related to use of supplemental 
oxygen.    
 
 
*Two of these events involved hospitalization:  overnight hospitalization with humerus fracture and 6-day 









   
Expected, related events   
Fires related to oxygen use 2 0.08 
Burn from smoking around oxygen equipment 3 0.12 
Burn from using oxygen equipment around open flame 1 0.04 
Burn from liquid oxygen frost 4 0.16 
Nosebleed 9 0.35 
Tripping/falling over oxygen equipment 23* 0.90 
   
Total no. of expected, related events 42 1.64 
   
Unexpected, related events   
Blisters, ear pain 3 0.12 
Dry eyes 1 0.04 
Funny feeling in sinus area 1 0.04 
Increased intestinal gas 1 0.04 
Headache 2 0.08 
Nausea 1 0.04 
   
Total no. of unexpected, related events 9 0.35 
   
Total no. of all related events 51 1.99 
   
Total no. of patients ever using supplemental oxygen during follow-up 490  
No. (%) reporting at least 1 related adverse event 42 (8.6%)  
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